866-997-4948(US-Canada Toll Free)

Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

Published By :

DelveInsight

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 100 Pages


DelveInsights Report, Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Glioblastoma Multiforme (GBM) Report is to understand the market and pipeline status of the drugs around the Glioblastoma Multiforme (GBM) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsights Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Glioblastoma Multiforme (GBM). While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
SCOPE:
A snapshot of the global Market and Phase III therapeutics scenario for Glioblastoma Multiforme (GBM).
A review of the marketed products under prescription for Glioblastoma Multiforme (GBM), regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Glioblastoma Multiforme (GBM) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Glioblastoma Multiforme (GBM) drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Glioblastoma Multiforme (GBM) drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Glioblastoma Multiforme (GBM) drugs.
Coverage of Glioblastoma Multiforme (GBM) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure to 2018.
Reasons to buy
Evaluate the marketing status and exclusivity details of Glioblastoma Multiforme (GBM) key products to exploit opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for Glioblastoma Multiforme (GBM).
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Glioblastoma Multiforme (GBM).
API intelligence over marketed drugs forGlioblastoma Multiforme (GBM)and gaining primary intelligence over active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Glioblastoma Multiforme (GBM).
Uncovering opportunities in the rapidly growing US market.
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Glioblastoma Multiforme (GBM)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Glioblastoma Multiforme (GBM)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Glioblastoma Multiforme (GBM)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Table


Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type, 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2017
Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status, 2017
Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, Europe by Country, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, India by State, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, China by Province, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers by Geography 2017
Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales-2018 (in million USD)
API Manufacturers for Drug, 2017
Phase III Drugs for Glioblastoma Multiforme (GBM), 2017
Discontinued Drugs for Glioblastoma Multiforme (GBM), 2017

List of Chart


Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2017
Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, Europe by Country, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, India by State, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, China by Province, 2017
Glioblastoma Multiforme (GBM) Drugs, API Manufacturers by Geography 2017
Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales 2018 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *